The Breakthrough
immunotherapy and the race to cure cancer
-
- 15,99 €
Publisher Description
Detailing the cutting-edge work that was awarded the 2018 Nobel Prize for Medicine.
New York Times bestselling author Charles Graeber tells the astonishing story of the group of scientists working on a code that can enable the human immune system to fight — and perhaps even cure — cancer.
For decades, scientists have puzzled over one of medicine’s greatest mysteries: why doesn’t our immune system fight cancer the way it does other diseases? The answer is a series of tricks that cancer has developed to turn off normal immune responses — tricks that scientists have only recently discovered, and now are learning to defeat. We are in the midst of a revolution in our understanding of cancer and how to beat it.
Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognise and defeat cancer, as told through the experiences of the patients, physicians, and immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, and the definitive account of a historic moment in medical science.
PUBLISHERS WEEKLY
"Hype can be dangerous, just as false hope can be cruel," journalist Graeber (The Good Nurse) writes in this lucid and informed report on how doctors and medical researchers, advancing beyond a "cut, burn, and poison" approach to fighting cancer, discovered how to use the human immune response to attack mutant cells. Graeber recalls the "crushing failure" cancer immunotherapy suffered in the 1970s, and the giddy over-optimism seen in the 1980s before cancer breakthroughs such as interferon drugs went bust and immunotherapy research was left to a "handful of true believers." His narrative moves from the grueling stories of research experiments and drug trials through which pharmaceutical companies "spread their bets" over a variety of potential drugs to the even more grueling experiences of cancer patients. Graeber focuses on the scientific developments and the "mind-blowing possibilities," such as cellular therapy, in which living cells are used to fight cancer. Noting there are 940 immunotherapeutic drugs being tested by more than a half million patients, with another 1,064 drugs in the preclinical stage, he predicts the cancer cure lies in the personalized immunotherapy route. Graeber gives readers a basis for both understanding the challenges involved and for cautious optimism that a cure can be found.)
